Table 3.
Probability of death in subgroups and risk factors in transplant patients with COVID-19
| n | Probability of death within 28 days (95% CI) |
Hazard ratio (95% CI) |
|||
|---|---|---|---|---|---|
| Crude | Adjusteda | Crude | Adjusteda | ||
| Age at COVID-19 diagnosis, yr | |||||
| 0–64 | 635 | 11.9 (9.5–14.9) | 11.9 (9.2–14.5) | 1 | 1 |
| 65–74 | 260 | 29.3 (23.9–35.6) | 28.6 (22.6–34.1) | 2.78 (2.00–3.88) | 2.72 (1.95–3.80) |
| ≥75 | 118 | 44.3 (35.7–53.9) | 43.2 (33.3–51.6) | 5.16 (3.59–7.42) | 5.10 (3.55–7.34) |
| Sex | |||||
| Female | 351 | 22.2 (18.0–27.1) | 18.4 (14.2–22.5) | 1 | 1 |
| Male | 662 | 19.1 (16.2–22.5) | 15.8 (12.8–18.7) | 0.83 (0.62–1.11) | 0.82 (0.61–1.1) |
| Primary renal disease | |||||
| Glomerulonephritis | 224 | 16.4 (12.0–22.3) | 14.9 (10.0–19.5) | 1 | 1 |
| Diabetes | 130 | 30.6 (23.0–40.1) | 21.7 (14.4–28.3) | 2.03 (1.27–3.24) | 1.52 (0.95–2.44) |
| Hypertension/RVD | 107 | 27.9 (20.1–38.0) | 20.1 (12.4–27.2) | 1.88 (1.14–3.10) | 1.44 (0.86–2.39) |
| Other | 552 | 17.8 (14.8–21.4) | 15.8 (12.5–18.9) | 1.13 (0.76–1.67) | 1.10 (0.74–1.64) |
| Year of KRT start (France only) | |||||
| <2014 | 370 | 18.7 (14.9–23.2) | 18.3 (13.0–23.3) | 2.39 (0.59–9.76) | 2.89 (0.7–11.92) |
| 2014–2017 | 115 | 12.7 (7.5–21.0) | 14.2 (8.3–19.6) | 1.24 (0.59–2.61) | 1.26 (0.60–2.67) |
| 2018–2020 | 27 | 7.6 (1.9–27.0) | 21.2 (13.4–28.2) | 1 | 1 |
| Year of transplantation (Spain only) | |||||
| <2014 | 241 | 22.6 (17.7–28.6) | 18.3 (13.0–23.3) | 0.70 (0.45–1.08) | 0.83 (0.53–1.30) |
| 2014–2017 | 143 | 18.3 (12.8–26.0) | 14.2 (8.3–19.6) | 0.76 (0.58–0.98) | 0.81 (0.63–1.06) |
| 2018–2020 | 117 | 30.8 (23.0–40.4) | 21.2 (13.4–28.2) | 1 | 1 |
| Country | |||||
| France | 512 | 16.8 (13.7–20.5) | 14.2 (10.2–17.9) | 0.73 (0.55–0.97) | 0.78 (0.58–1.05) |
| Spain | 501 | 23.3 (19.7–27.4) | 19.6 (15.5–23.5) | 1 | 1 |
CI, confidence interval; COVID-19, coronavirus disease 2019; HD, hemodialysis; KRT, kidney replacement therapy; PD, peritoneal dialysis; RVD, renovascular disease.
a
The model for age was adjusted for sex and country; the model for sex was adjusted for age and country; the model for primary renal disease (PRD) was adjusted for age, sex, and country; the model for year of KRT start and year of transplant was adjusted for age, sex, PRD, and country; and the model for country was adjusted for age, sex, PRD, and year of KRT start (or transplantation in Spain).